(ChemotherapyAdvisor) – Electrochemotherapy controls local tumors in head and neck cancers, according to an announcement from OncoSec Medical, Inc. The company, which is developing its advanced-stage OncoSec Medical System (OMS) ElectroOncology therapies to treat solid tumors, made the announcement today, based on results presented at the 5th European Conference on Head and Neck Oncology in Poznan, Poland on Friday, April 20, 2012. Presented was a positive interim analysis of data from 81 subjects in a Phase 4 study of primary and locally recurrent squamous cell carcinoma of the head and neck treated with OMS ElectroChemotherapy in Europe.
The primary goal, which was to assess the ability of the OMS ElectroChemotherapy to control growth or recurrence of the cancer eight months following treatment, was met and demonstrated by the achievement of local tumor control in 46/49 (94%) primary tumors and 12/21 (57%) recurrent tumors in a safe and well-tolerated manner. Secondary endpoints included an assessment of the patient’s ability to swallow, normalcy of diet, ability to eat in public by the Performance Status Scale for Head and Neck cancer (PSSHN); general quality of life was assessed by the European Organization for Research and Treatment of Cancer Core QOL questionnaire (EORTC QLQ).
“Treated patients showed a mean overall score of 264 at baseline vs. 249 at eight months (P=0.3412), indicating no significant difference in quality of life following treatment with OMS ElectroChemotherapy. The conclusions regarding these endpoints were positive and will be reviewed in a final publication.”